Publication Name	World Journal of Gastroenterology
Manuscript ID	122545
DOI	10.3748/wjg.122545
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Inflammation and steatosis differentially modulate antiviral efficacy in chronic hepatitis B with metabolic dysfunction-associated steatotic liver disease
Manuscript Source	Unsolicited Manuscript
All Author List	Ming-Hui Zeng, Fang-Yuan Tian, Shi-Yun Hu, Jia-Xin Han, Lian-Xin Xu, Li Chu, Wen-Tao Kuai, Yu-Qin Li, Yi-Chen Wang, Yu-Qiang Mi, Ming-Hua Zheng and Liang Xu
Funding Agency and Grant Number	Funding Agency Grant Number Tianjin Municipal Education Commission Scientific Research (Natural Sciences) Program Project No. 2023KJ016 Tianjin Key Medical Discipline Construction Project No. TJYXZDXK-3-019B Natural Science Foundation of Tianjin No. 23JCYBJC00950 Research project in Key Areas of Traditional Chinese Medicine in 2024 No. 2024022
Corresponding Author	Liang Xu, Department of Hepatology and Oncology, The Second People’s Hospital Affiliated to Tianjin Medical University, No. 7 Sudi South Road, Tianjin 300192, China. xuyangliang2004@sina.com
Key Words	Chronic hepatitis B; Metabolic dysfunction-associated steatotic liver disease; Steatotic liver disease; Nucleos(t)ide analogues; Liver biopsy
Core Tip	This 5-year biopsy-supported study shows that the presence of metabolic dysfunction-associated steatotic liver disease (MASLD) generally attenuates nucleoside analogues antiviral efficacy and biochemical remission in patients with chronic hepatitis B (CHB). We also found that hepatic steatosis delays complete virological response whereas inflammation accelerates it. This study provides crucial clinical insights, showing that non-inflammatory MASLD-CHB is a clinically challenging phenotype that requires closer monitoring and optimized management.
Citation	Zeng MH, Tian FY, Hu SY, Han JX, Xu LX, Chu L, Kuai WT, Li YQ, Wang YC, Mi YQ, Zheng MH, Xu L. Inflammation and steatosis differentially modulate antiviral efficacy in chronic hepatitis B with metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2026; In press DOI: https://doi.org/10.3748/wjg.122545
PDF	122545-in-press.pdf

Received	2026-04-27 08:12
Peer-Review Started	2026-04-27 08:12
First Decision by Editorial Office Director	2026-05-13 07:37
Return for Revision	2026-05-13 07:37
Revised	2026-06-02 16:21
Publication Fee Transferred	2026-06-04 09:46
Second Decision by Editor	2026-06-17 02:38
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-06-17 08:17
Articles in Press	2026-06-17 08:17
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com